WILMINGTON, MASSACHUSETTS--(MARKET WIRE)--Aug 28, 2007 -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions today announced that Bob Doman, President & CEO will present at the Roth Capital Partners Annual New York Institutional Investor Conference. The conference is being held at the Westin New York at Times Square on September 5-6, 2007. Mr. Doman is scheduled to present at 4:00 p.m. Eastern Time on Wednesday, September 5.
